According to a report published by the Center for Infectious Disease Research & Policy (CIDRAP), “At least 5 to 6 months into a pandemic, until a vaccine can be made and distributed, antiviral drugs for influenza (ie, antivirals) will be the only pharmacologic option for potentially preventing, shortening, or reducing the severity of illness among employees. Given grim estimates of 30% absentee rates, offering employees antivirals as part of a prevention or treatment strategy could appear to be a cost-effective way of both reducing worker absenteeism and bolstering employees' confidence in their company. In a recent poll of 120 preparedness professionals attending the CIDRAP summit on business preparedness for pandemic influenza in February, 37% of the participants (many from Fortune 500 companies), said their firms had purchased or were planning to purchase antivirals for distribution to employees during a pandemic.” (May 11, 2007: CIDRAP News: http://www.cidrap.umn.edu/cidrap/content/influenza/biz-plan/news/051107antivirals.html)
Should dental offices consider stockpiling and potentially distribute antivirals (e.g. Tamiflu) to their employees? Although it is a difficult decision based on issues such as supply, distribution and timing, Dynamic Dental Safety recommends that dental offices should at least explore this option as part of a comprehensive emergency preparedness plan.
